Herceptin acts as an anti-angiogenic cocktail
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Malignant tumours secrete factors that enable them to commandeer their own blood supply (angiogenesis), and blocking the action of these factors can inhibit tumour growth. But because tumours may become resistant to treatments that target individual angiogenic factors by switching over to other angiogenic molecules, a cocktail of multiple anti-angiogenic agents should be more effective. Here we show that herceptin, a monoclonal antibody against the cell-surface receptor HER2 (for human epidermal growth factor receptor-2; ref. 4), induces normalization and regression of the vasculature in an experimental human breast tumour that overexpresses HER2 in mice, and that it works by modulating the effects of different pro- and anti-angiogenic factors. As a single agent that acts against multiple targets, herceptin, or drugs like it, may offer a simple alternative to combination anti-angiogenic treatments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Certain molecularly targeted agents, such as the anti-HER2 antibody trastuzumab, and metronomic chemotherapy can also induce vascular normalization via upregulation of thrombospondin expression28,116,117.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [116]
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Self-citationLeakage-Resistant Blood Vessels in Mice Transgenically Overexpressing Angiopoietin-1
Thurston, G., Suri, C., Smith, K., McClain, J., Sato, T. N., Yancopoulos, G. D., & McDonald, D. M. (1999) · Science · doi:10.1126/science.286.5449.2511 · Cited by 1,359
Tumor Induction of VEGF Promoter Activity in Stromal Cells
Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996
Self-citationThrombospondins as matricellular modulators of cell function
Bornstein, P. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12749 · Cited by 470
Allgayer, H., Babic, R., Gruetzner, K. U., Tarabichi, A., Schildberg, F. W., & Heiss, M. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2201 · Cited by 276
‘Accidental’ anti-angiogenic drugs
Kerbel, R. S., Viloria-Petit, A., Klement, G., & Rak, J. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00092-7 · Cited by 182
Angiogenic Heterogeneity: Regulation of Neoplastic Angiogenesis by the Organ Microenvironment
Fidler, I. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1040 · Cited by 109
Jain, R. K., & Carmeliet, P. (2001) · Scientific American · doi:10.1038/scientificamerican1201-38 · Cited by 94
Self-citation
Research works printed but not linked: 1
- Jain, R. K., Munn, L. L. & Fukumura, D. Nature Rev. Cancer (in the press).
Cited by
Items 501–600 of 622
Wojdyła-Mamoń, A. M., Zimny, J., Romanowska, J., Kraszewski, A., Stawiński, J., Bieganowski, P., & Guranowski, A. (2015) · Biochemical Journal · doi:10.1042/bj20141568 · Cited by 2
Adjuvant Trastuzumab for HER2-Positive Early Breast Cancer
Palmieri, F. M., Myatt, C. V., & Perez, E. A. (2010) · Clinical journal of oncology nursing · doi:10.1188/10.cjon.326-336 · Cited by 2
Grépin, R., & Pagès, G. (2009) · Journal de la Société de Biologie · doi:10.1051/jbio/2009022 · Cited by 4
Personalized Therapies for Cancer Treatment
Nair, L., & Gonzalez-Angulo, A. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-416603-5.00013-4 · Cited by 2
Henary, H. A., George, G. C., Wheler, J. J., Naing, A., Piha-Paul, S. A., Fu, S., Mistry, R., Zinner, R., Kurzrock, R., & Hong, D. S. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2824-6 · Cited by 3
Therapeutic Antibodies in Clinical Use and Leading Clinical Candidates
Zhang, N., Williams, B. R., Lü, P., An, Z., & Chin, C. (2009) · Wiley eBooks · doi:10.1002/9780470485408.ch31 · Cited by 2
Hsu, Y., Mohanty, S., Litvinchuk, A. V., & Hou, Q. (2004) · Hybridoma and Hybridomics · doi:10.1089/153685904774129720 · Cited by 2
Studies of Transforming Growth Factor Alpha in Normal and Abnormal Growth
Hallbeck, A. (2007) · DiVA (Linkoping University) · Cited by 5
Azim, H., & Azim, H. A. (2007) · PubMed · Cited by 2
Heymach, J. V., Zurita‐Saavedra, A., Kopetz, S., Cascone, T., Nilsson, M. B., & Guijarro, I. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm017.pub2 · Cited by 2
Trastuzumab emtansina (T-DM1) en cáncer de mama HER2 positivo
Nervo, A., Costanzo, V., & Chacon, R. D. (2013) · Oncología Clínica · doi:10.56969/oc.v18i4.111 · Cited by 2
Antiangiogenic Therapy for Normalization of Tumor Vasculature and Microenvironment
Jain, R. K., & Duda, D. G. (2007) · Springer eBooks · doi:10.1007/978-3-540-33177-3_33 · Cited by 1
Self-citationTrastuzumab as Adjuvant Treatment for Early Stage HER-2-positive Breast Cancer
Bartsch, R., & Steger, G. G. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0094-1_2 · Cited by 1
Untch, M., & Jackisch, C. (2009) · Der Onkologe · doi:10.1007/s00761-009-1648-6 · Cited by 1
Tumor Growth and Cell Proliferation
Łoś, M., Rashedi, I., Panigrahi, S., Klonisch, T. C., & Schulze‐Osthoff, K. (2009) · Medical radiology · doi:10.1007/978-3-540-74386-6_2 · Cited by 2
Growth inhibition of breast cancer in rat by AAV mediated angiostatin gene
Li, R., Chen, H., & Ren, C.-S. (2007) · Chinese Journal of Cancer Research · doi:10.1007/s11670-007-0108-3 · Cited by 1
Adjuvant Biologic Agents for Breast Cancer
Kaklamani, V., & Gradishar, W. J. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1145-5_25 · Cited by 1
Hong, M. C., Long, C., Tian, Y.-F., & Wu, M.-P. (2013) · Gynecology and Minimally Invasive Therapy · doi:10.1016/j.gmit.2013.07.001 · Cited by 1
Resistance to HER2-targeted therapy
Valadan, R., Rafiei, A., Tehrani, M., & Nejatollahi, F. (2013) · Research in Molecular Medicine · doi:10.18869/acadpub.rmm.1.1.1 · Cited by 1
MARKERS FOR THE EFFICIENCY OF BEVACIZUMAB THERAPY IN PATIENTS WITH DISSEMINATED COLON CARCINOMA
Fedyanin, M. Y., Tryakin, A. A., & Tyulyandin, S. А. (2012) · Russian Journal of Oncology · doi:10.17816/onco39970 · Cited by 1
Madu, C. O., & Lu, Y. W. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0131-6_1 · Cited by 1
A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer
Church, D. N., & Price, C. G. A. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s35 · Cited by 1
Role of Ceramide Kinase in Breast Cancer Progression
Payne, A. W. (2014) · ScholarlyCommons (University of Pennsylvania) · Cited by 1
Targeting Pro-Angiogenic TGF-β Signaling in the Tumor Microenvironment
Pietras, K., & Cunha, S. I. (2013) · Springer eBooks · doi:10.1007/978-4-431-54409-8_19 · Cited by 2
Inhibitors of tumor angiogenesis
Harris, A. L., & Generali, D. (2008) · Elsevier eBooks · doi:10.1016/b978-012369448-5.50018-5 · Cited by 1
Trastuzumab beyond progression in HER2‐positive metastatic breast cancer
AL-Naqqash, M. A. M., Al‐Serarati, W. J., & Kareem, T. F. (2021) · The Breast Journal · doi:10.1111/tbj.14157 · Cited by 1
Mechanisms of resistance to lapatinib in HER2 positive breast cancer
McDermott, M. S. J. (2012) · Dublin City University Open Access Institutional Repository (Dublin City University) · Cited by 1
Aird, K. M. (2010) · DukeSpace (Duke University) · Cited by 2
García‐Albéniz, X., Martinez-Fernandez, A., & Gascón, P. (2007) · Targeted Oncology · doi:10.1007/s11523-007-0062-5 · Cited by 1
Fasih, A. (2011) · TSpace (University of Toronto) · Cited by 2
Maadi, H. (2020) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-74bb-e058 · Cited by 1
Braman, N. M., Prasanna, P., Bera, K., Alilou, M., Khorrami, M., Leo, P., Etesami, M., Vulchi, M., Turk, P., Gupta, A. B., et al. (2023) · doi:10.1158/1078-0432.c.6532814.v1 · Cited by 1
Okutur, S. K. (2011) · Istanbul Science University (Istanbul Bilim University)
Monoclonal Antibody Strategies for Targeting HER2
Albanell, J., Ross, J. S., Pronk, L. C., & Gascón, P. (2007) · Humana Press eBooks · doi:10.1385/1-59259-893-5:627
HER2-Positive Metastatic Breast Cancer: Second-Line Treatment
Álvarez, R. H. (2013) · doi:10.1007/978-1-907673-94-8_5
Targeting HER-2 Signaling Network: Implication in Radiation Response
Ah, I. (2011) · InTech eBooks · doi:10.5772/20538
Targeting the HER Family of Receptors in the Treatment of Advanced Breast Cancer
Baselga, J. M., & Cortés, J. (2007) · Springer eBooks · doi:10.1007/978-3-540-28266-2_32
Antibody‐Mediated Drug Delivery Systems for Breast Cancer Therapeutics
Alcivar, L. M., & Pathak, Y. V. (2012) · doi:10.1002/9781118229019.ch3
Chemical and Biological Strategies for Improving the Sensitivity of SPIO-Enhanced MR Imaging
Elias, A. (2011) · ScholarlyCommons (University of Pennsylvania)
HER2FISH analysis on a skeletal metastasis: a case report and technical review
McMahon, L. A., Henry, J., Yang, Q., Baxter, L., Blaszkowski, R., Jackson, M., Tillett, E., & Hicks, D. G. (2015) · Journal of Histotechnology · doi:10.1179/2046023615y.0000000011
Cocktail drug delivery chip for cancer drug screening
Chen, Y., Wu, R., Yang, C., & Tseng, F. (2015) · International Conference on Solid-State Sensors, Actuators and Microsystems · doi:10.1109/transducers.2015.7181028
Treatment with Trastuzumab Beyond Progression
von Minckwitz, G., & Pirvulescu, C. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0094-1_4
Targeted Therapy For Breast Cancer
Atieh, D. M., & Vahdat, L. T. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-337-0_14
MONOCLONAL ANTIBODY TO HER-2 IN BREAST CANCER
Esteva, F. J., & Hortobágyi, G. N. (2007) · Elsevier eBooks · doi:10.1016/b978-012369393-8/50005-5
Monoclonal and Bispecific Antibodies in Combination with Radiotherapy for Cancer Treatment
Azria, D., Larbouret, C., Robert, B., Özşahin, M., Dubois, J., & Pèlegrin, A. (2004) · Springer eBooks · doi:10.1007/978-1-4419-8877-5_6
Immunohistochemical Study of C-erbB-2 and VEGF Expression in Non-Small Cell Lung Cancer
Shin, J. W., Ha, K. W., Choi, J. C., Kim, J. Y., Park, I. W., Choi, B. W., & Yoo, J. H. (2007) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2007.62.1.43
Trastuzumab in the adjuvant setting: a practical review
Rossi, V., Redana, S., Milani, A., Geuna, E., Valabrega, G., Aglietta, M., & Montemurro, F. (2011) · Therapy · doi:10.2217/thy.10.65
A Case of Herceptin Cardiotoxicity
Cobleigh, M., & Somberg, J. C. (2004) · American Journal of Therapeutics · doi:10.1097/00045391-200401000-00013
Targeted Therapies for HER2 Breast Cancer: A View of the Landscape
Rana, V., & Swaby, R. F. (2011) · Current Breast Cancer Reports · doi:10.1007/s12609-010-0037-x
Treatment of hormone receptor negative breast cancer
Andreopoulou, E., & Hortobágyi, G. N. (2010) · Hot Topics in Oncology · doi:10.4147/hto-100707
The expression and molecular functions of LRIG proteins in cancer and psoriasis
Karlsson, T. (2013) · DiVA at Umeå University (Umeå University)
Present and Emerging Targeted Therapy for Metastatic Breast Cancer
Lorusso, V., Marech, I., Giampaglia, M., Tinelli, A., & Chiurì, V. E. (2012) · Journal of cancer research updates · doi:10.6000/1929-2279.2012.01.01.14 · Cited by 2
Life After Trastuzumab: Neu Strategies For Her2-Positive Breast Cancer
Higa, G. M., & Cheng, R. M. (2013) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.810571
Pharmacology and Clinical Development of New Molecularly Targeted Agents
Giovannetti, E., & Galvani, E. (2015) · Current clinical pathology · doi:10.1007/978-1-4939-2047-1_3
Possibilities of Targeted Therapies for Brain Metastasis
Winkler, F. (2012) · Cancer metastasis · doi:10.1007/978-94-007-5291-7_6
Tyrosine kinase - Role and significance in Cancer
Nagar, S. (2004)
Molecular Neurooncology and Neoangiogenesis of Malignant Gliomas
Hutterer, M., & Stockhammer, G. (2009) · Springer eBooks · doi:10.1007/978-3-642-00475-9_2
Russo, C., & Omar, D. (2011) · Cited by 1
Radiation Biology of Tumor and Normal Tissues
Suit, H. D., & Loeffler, J. S. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6744-2_8
Trastuzumab Resistance in Breast Cancer
Morgillo, F., Orditura, M., Troiani, T., Martinelli, E., Vita, F. D., & Ciardiello, F. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0094-1_3
Oliveras‐Ferraros, C. (2013) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Targeted Therapy in Hematologic Malignancies
Zehnbauer, B. A., & Nasser, M. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-262-9_9
Generation of IgE-based immunotherapies against HER-2 overexpressing tumours
Knittelfelder, R. (2010) · University of Vienna · doi:10.25365/thesis.10543
Dinh, P., Tomasello, G., & Piccart, M. J. (2010) · Springer eBooks · doi:10.1007/978-3-540-69743-5_20
Cases for 3D Cultures in Drug Discovery
Kisaalita, W. (2010) · CRC Press eBooks · doi:10.1201/ebk1420073492-c12
Basics of Theranostics in Tumor
Zou, H., Liu, Y., & Zhao, S. (2016) · Co-published with HEP eBooks · doi:10.1142/9789814635424_0002
Krüppel-like Factor 5 (KLF5) and Tumor Angiogenesis
Tarapore, R. S., & Yang, Y. (2013) · CRC Press eBooks · doi:10.1201/b14842-10
(2013) · CRC Press eBooks · doi:10.1201/b14587-17
Razumienko, E. J. (2016) · TSpace (University of Toronto)
Use of genetically engineered mouse models in preclinical drug development
Creedon, H. (2015) · ERA
Generation and Characterization of Recombinantly Polysialylated Antibody
Chen, C. (2011) · Spiral (Imperial College London) · doi:10.25560/6970 · Cited by 1
Mason, J. K. (2015) · TSpace (University of Toronto)
Kaumaya, P. T. P., & Bekaii‐Saab, T. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12422-9
The use of Thrombospondin-1 Mimetic Peptides for the Treatment of Epithelial Ovarian Cancer
Campbell, N. (2012) · The Atrium (University of Guelph)
Korth, M. (2017) · OPen Access Repositorium der Universität Ulm (OPARU) (Ulm University) · doi:10.18725/oparu-4364
Zubac, D. P. (2010) · NORA - Norwegian Open Research Archives
Chapter 1: Nanotechnology Platforms and Physiological Challenges for Cancer Therapeutics
Hughes, G. A. (2017) · CRC Press eBooks · doi:10.1201/9781315114361-2
Lam, K. S. L. (2017) · TSpace (University of Toronto)
Breast Cancer Stem Cells: Tumourspheres and Implications for Therapy
Morrison, B. J. (2011) · Griffith Research Online · doi:10.25904/1912/1434
Сергеевна, Ф. Е., Savostikova, M. V., Нариманов, М. Н., Pashaev, A. A., Kirichenko, S. S., Музаффарова, Т. А., Кипкеева, Ф. М., & Karpukhin, A. V. (2017) · Clinical Medicine (Russian Journal) · doi:10.18821/0023-2149-2016-94-11-812-820
Aleem, M., Sharma, D., Sharma, D., Dan, S., Gupta, P., Fakhri, K. U., & Rizvi, M. M. A. (2020) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-6530-8.ch010 · Cited by 1
Nanoparticle theranostics targeting CLEC14A on tumour vasculature
Pearce, J. (2020) · University of Birmingham Institutional Research Archive (University of Birmingham) · Cited by 1
Faingold, D., Bakalian, S., & Russell-Hermanns, D. S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-3685-0_28
Heymach, J. V., Zurita‐Saavedra, A., Kopetz, S., Cascone, T., & Nilsson, M. B. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm017 · Cited by 1
Neurological complications of immunotherapy and monoclonal antibody therapy
Pïcca, A., & Psimaras, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821976-8.00009-8
HER2-positive metastatic breast cancer: second-line treatment
Álvarez, R. H. (2016) · Springer eBooks · doi:10.1007/978-3-319-28216-9_5 · Cited by 1
(2011) · Elsevier eBooks · doi:10.1016/b978-0-12-387819-9.00029-3
Ribatti, D. (2018) · Springer eBooks · doi:10.1007/978-3-319-92633-9_5
Komplementäre Therapieverfahren
Benninghoff, B., Birkenmeier, J., Folkman, J., Hager, E. D., Hajeck-Lang, B., Irmey, G., Kaltofen, S., Klingmüller, M., Kraft, K., Matthei, S., et al. (2006) · Elsevier eBooks · doi:10.1016/b978-343756420-8.50016-0
Franco, A. F. D. V., Malinverni, A. C. D. M., & Waitzberg, Â. F. L. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154917 · Cited by 1
Bui, I., Vivarelli, S., Falzone, L., Libra, M., & Bonavida, B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-816408-2.00002-6
Thakare, M. S. R., Tajne, P. M. V. C., Jiddewar, A. S., Adhau, M. S. M., & Raut, M. S. B. (2025) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-22915
Detecting vascular normalization in epithelial ovarian cancer
Mororó, J. D. S., Meira, D. D., Bizzo, S., Altoé, L. S. C., Casotti, M. C., Santana, G. M., Louro, L. S., Louro, T. E. S., Vicente, C. R., de Araújo, B. C., et al. (2025) · Medical Oncology · doi:10.1007/s12032-025-02929-5 · Cited by 2
Friedländer, E. (2008) · University of Debrecen Electronic Archive (University of Debrecen)
Tishechkin, A. K., & Caterino, M. S. (2009) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.191874
Angeli, E., Paris, J., Tilly, O. L., Desvignes, C., Gapihan, G., Boquet, D., Pamoukdjian, F., Hamdan, D., Rigal, M., Poirier, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26706396
Metadata
- Authors
- Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Nature
- Published
- 2002-03
- Volume
- 416
- Issue
- 6878
- Pages
- 279-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2034801324
- Cited by
- 623
- References
- 11
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 26 · 2023: 10 · 2022: 14 · 2021: 12 · 2020: 18 · 2019: 12 · 2018: 20 · 2017: 23 · 2016: 18 · 2015: 24 · 2014: 27 · 2013: 30 · 2012: 35
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (P01CA080124)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- trastuzumab, anti-angiogenic therapy, HER2, human epidermal growth factor receptor 2, tumor angiogenesis, tumor regression, combination therapy, breast cancer, monoclonal antibodies, tumor resistance
- MeSH terms
- Trastuzumab, Animals, Antibodies, Monoclonal, Humans, Lymphokines, Mammary Neoplasms, Experimental, Neovascularization, Pathologic, Signal Transduction, Gene Expression, Endothelial Growth Factors, Mice, SCID, Genes, erbB-2, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.